A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Lanifibranor (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Acronyms NATIVE
- Sponsors Inventiva Pharma
- 10 Jun 2017 Biomarkers information updated
- 03 Jan 2017 Planned number of patients changed from 300 to 225, according to Inventiva Pharma media release.
- 03 Jan 2017 Status changed from not yet recruiting to recruiting, according to Inventiva Pharma media release.